{"schema_version":"secwatch.filing_event.v1","accession":"0001701541-24-000028","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.165371+00:00","generated_at":"2026-05-31T12:20:11.898113+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Black Diamond Q2 2024 net loss $19.9M; cash runway into Q4 2025; Phase 2 data on track","bullets":["Cash, equivalents, investments $123.0M at June 30, 2024, down from $131.4M at Dec 31, 2023; runway into Q4 2025.","Net loss $19.9M in Q2 2024 vs $19.2M in Q2 2023; R&D expenses decreased to $12.6M from $13.2M.","Initial Phase 2 data for BDTX-1535 in 2L/3L EGFRm NSCLC on track for later Q3 2024; 1L data in Q1 2025.","Initial Phase 1 data for BDTX-4933 in KRASm NSCLC on track for Q4 2024; ESMO poster in September 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001701541-24-000028","json":"https://secwatch.observer/filing/0001701541-24-000028.json","markdown":"https://secwatch.observer/filing/0001701541-24-000028.md","text":"https://secwatch.observer/filing/0001701541-24-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000170154124000028/0001701541-24-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000170154124000028/bdtx-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:20:11.898113+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}